Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
ALKSNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) ("Alkermes") and...
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
ALKS(NASDAQ:ALKS) — Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia — — Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 —...
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
ALKS– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00...
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
ALKSNeedham Initiates Coverage On Alkermes with Buy Rating, Announces Price Target of $45
ALKSRBC Capital Maintains Sector Perform on Alkermes, Raises Price Target to $40
ALKSBaird Maintains Outperform on Alkermes, Raises Price Target to $41
ALKSAlkermes Affirms FY2025 GAAP EPS Guidance of $1.03-$1.21 vs $1.12 Est; Affirms FY2025 Sales Guidance of $1.34B-$1.43B vs $1.39B Est
ALKSAlkermes Q1 GAAP EPS $0.13 Beats $0.05 Estimate, Sales $306.51M Beat $304.12M Estimate
ALKSBeyond The Numbers: 6 Analysts Discuss Alkermes Stock
ALKSUBS Maintains Neutral on Alkermes, Lowers Price Target to $33
ALKSAlkermes Has Initiated Vibrance-3 Phase 2 Study Evaluating The Safety And Efficacy Of ALKS 2680 Compared To Placebo In Adults With Idiopathic Hypersomnia
ALKSWhat 5 Analyst Ratings Have To Say About Alkermes
ALKSDeutsche Bank Maintains Buy on Alkermes, Raises Price Target to $52
ALKSRBC Capital Initiates Coverage On Alkermes with Sector Perform Rating, Announces Price Target of $40
ALKSGoldman Sachs Maintains Buy on Alkermes, Raises Price Target to $32
ALKSHC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $46 Price Target
ALKSAlkermes Forecasts 2025 Sales Of $1.34B-$1.43B Versus Consensus Of $1.40B
ALKSAlkermes Q4 2024 Adj EPS $1.04 Beats $0.79 Estimate, Sales $429.99M Beat $379.74M Estimate
ALKSAlkermes FY 2024 Adj EPS $2.92 Beats $2.66 Estimate, Sales $1.56B Beat $1.51B Estimate
ALKSCharter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
ALKSA Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts
ALKSStifel Upgrades Alkermes to Buy, Raises Price Target to $36
ALKSLooking Into Alkermes's Return On Capital Employed
ALKSBenzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter.
SVB Leerink Maintains Market Perform on Alkermes, Raises Price Target to $27
ALKSHC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $32
ALKS